Physician profile
Jonathan Song
NPI 1508957564
$3,671.09
in general payments reported to CMS, 2019-2025
13 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,165 · 2020: $163 · 2021: $122 · 2022: $217 · 2023: $211 · 2024: $256 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $1,250.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $818.79 | 2019-2025 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Regeneron Healthcare Solutions, INC. | $494.62 | 2019-2025 | Eylea Hd |
| Alcon Vision LLC | $490.48 | 2019-2025 | Centurion, Clareon |
| Ivantis, INC | $130.36 | 2019 | |
| Kala Pharmaceuticals, INC. | $124.86 | 2019 | |
| Shire North American Group INC | $115.39 | 2019 | |
| Glaukos Corporation | $84.18 | 2019 | |
| Biotissue Holdings INC. | $81.59 | 2022 | |
| Abbott Laboratories | $43.24 | 2024-2025 | Proclaim |
| Allergan, INC. | $20.30 | 2019 | |
| Rockwell Medical, INC. | $16.45 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.